Targeting tauopathy with engineered tau-degrading intrabodies

Keyphrases

• Tauopathy 100%
• Intrabody 100%
• Anti-tau 60%
• Human tau 40%
• Immunotherapeutic Approaches 30%
• Tau Pathology 20%
• ScFv 20%
• Tau Transgenic Mouse 20%
• Pathological tau 20%
• Cytosol 20%
• Mouse Model 10%
• Protein Level 10%
• Adenovirus 10%
• Protein Degradation 10%
• Central Nervous System 10%
• Tau Antibodies 10%
• Neurodegenerative Diseases 10%
• Tau Aggregates 10%
• Neurofibrillary Tangles 10%
• Tau Deposition 10%
• Cell-intrinsic 10%
• Intrinsic Mechanism 10%
• Primary Neuronal Culture 10%
• Ubiquitin 10%
• Specific Domain 10%
• Tau Protein 10%
• Main Components 10%
• Human Expression 10%
• Passive Immunity 10%
• Enhanced Efficacy 10%
• Degradation Capacity 10%
• Associated Pathologies 10%
• Single-chain Variable Fragment 10%
• Aging Men 10%
• Non-modified 10%

Biochemistry, Genetics and Molecular Biology

• Tau 100%
• Intrabody 100%
• Transgenic Mouse 8%
• Mouse Model 4%
• Animal Model 4%
• Protein Catabolism 4%
• Ubiquitin 4%
• Proteasome 4%
• Single-Chain Variable Fragment 4%
• Adeno Associated Virus 4%
• Tau Protein 4%
• Nerve Cell Culture 4%
• Neurofibrillary Tangle 4%